BenzingaSeptember 21, 2026 at 5:07 AM NYLast Month
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
